Interactions on record — worth a quick check against your medications. Based on 3 of 5 ingredients. Check your meds →
Dietary supplement

Organic Infant Liquid Probiotic 100 Million CFU Unflavored Ingredients & Drug Interactions

by Mary Ruth’s

Liquid Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Organic Infant Liquid Probiotic 100 Million CFU Unflavored is a dietary supplement by Mary Ruth’s with 5 active ingredients. Its ingredients are commonly taken for digestive health and regularity, irritable bowel syndrome (ibs), diarrhea (including antibiotic-related).Based on those ingredients, 182 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Bifidobacterium longum infantis, Bifidobacterium bifidum, Bacillus coagulans Unique IS-2. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Organic Infant Liquid Probiotic 100 Million CFU Unflavored by Mary Ruth’s

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 5 active ingredients.
  • “Proprietary Probiotic Blend” is a proprietary blend — the label gives one combined amount (2.50 mg) without saying how much of each component you get.

This product has five active ingredients: a proprietary probiotic blend containing Bifidobacterium longum infantis, Bifidobacterium bifidum, Bifidobacterium animalis lactis, Lactobacillus reuteri, and Bacillus coagulans Unique IS-2. These are live beneficial bacteria meant to support your infant's digestive health.

The liquid is carried in medium chain triglyceride oil, with alfalfa grass as an additional ingredient.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: gut health and immune health.
  • We looked for evidence on: Abdominal pain, Antibiotic-associated diarrhea, Colic, Clostridioides difficile infection, Common cold, Constipation — and 4 related terms.
  • The strongest evidence on file: Bacillus Coagulans is rated "Possibly Effective" for Constipation (Natural Medicines).
  • Also on file: Bacillus Coagulans is rated "Insufficient Reliable Evidence To Rate" for Antibiotic-associated diarrhea, Dyspepsia, Flatulence, Rotaviral diarrhea, and more.

Evidence for these bacteria in infants is limited. Bifidobacterium bifidum is possibly effective for irritable bowel syndrome and respiratory tract infections, and Bacillus coagulans is possibly effective for constipation and irritable bowel syndrome.

For the other uses listed — cognitive decline, hay fever, antibiotic-associated diarrhea, anxiety, asthma, and athletic performance — the evidence isn't established in the data we hold.

The evidence, ingredient by ingredient Bifidobacterium Longum Bifidobacterium Bifidum Bacillus Coagulans

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 3 of the 3 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 3 of 3.
  • General safety write-ups exist for 3 of 3.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

These probiotics are generally well tolerated in healthy infants, but caution is advised for seriously ill or immune-compromised infants. Rare cases of infection (bacteremia and sepsis) have been reported in critically ill infants using probiotics, especially preterm infants.

Rare side effects when taken by mouth include abdominal discomfort, bloating, flatulence, constipation, and very rarely a dry cough. Limited safety data exist, so use only with your doctor's guidance.

For breastfeeding, Bifidobacterium bifidum is marked possibly safe, but data are limited — check with your doctor first.

Side effects, ingredient by ingredient Bifidobacterium Longum Bifidobacterium Bifidum Bacillus Coagulans

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 3 of the 3 matched ingredients can interact with medications — Bacillus Coagulans, Bifidobacterium Bifidum, Bifidobacterium Longum.
  • The most serious interaction on file is rated Moderate.
  • For scale: 182 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Antibiotic drugs are the main concern — they can kill the live bacteria in this probiotic and reduce how well it works. If your infant is prescribed antibiotics, space out the doses and mention this probiotic to your pediatrician or pharmacist so they can advise on timing.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

This probiotic is designed for infants and is generally well tolerated in healthy babies. If your infant is on antibiotics, separate the doses.

Because safety data are limited and rare infections have occurred in very ill or premature infants, talk with your pediatrician before starting, especially if your baby has a weakened immune system or serious illness.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 3 of 5 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Mar 25, 2025.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Organic Infant Liquid Probiotic 100 Million CFU Unflavored, straight from the product label.

Brand Mary Ruth’s
Barcode (UPC) 856645008587
Net contents 1 Fluid Ounce(s); 30 Milliliter(s)
Market status On market
Date entered into DSLD Mar 25, 2025
DSLD ID 327722
Product type Non-nutrient/non-botanical
Supplement form Liquid
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegan, Vegetarian, Organic, Infants/Baby (0 - 1 Year), Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Organic Infant Liquid Probiotic 100 Million CFU Unflavored by Mary Ruth’s, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Infants
Minimum serving Sizes:
0.25 mL
Maximum serving Sizes:
0.25 mL
Servings per container
120
UPC/BARCODE
856645008587
IngredientAmount% DV
Proprietary Probiotic Blend2.5 mg--
Bifidobacterium longum infantis0 NP--
Bifidobacterium bifidum0 NP--
Bifidobacterium animalis lactis0 NP--
Lactobacillus reuteri0 NP--
Bacillus coagulans Unique IS-20 NP--

Other ingredients: Medium Chain Triglyceride Oil, Alfalfa Grass

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Storage

No refrigeration required

Store in a cool, dry place

Suggested/Recommended/Usage/Directions

Suggested use: Product naturally settles. Shake gently before use. Ages 6-12 months, take up to 0.25 mL daily or as recommended by a physician or healthcare professional.

Precautions

Please avoid direct dropper contact to the skin or mouth in order to prevent product contamination and damage to the dropper. Do not exceed the recommended dose. Discontinue use if any negative reaction occurs.

Keep out of reach of children.

Please consult with a physician or healthcare professional before starting any health supplement, especially if pregnant or lactating, taking medication, or if you have a medical diagnosis.

General Statements

We genuinely care about all our customers. Learn more Contact us We love to hear from out customers. Questions? Feedback? Please feel free to call or email us!

Formulation

Gut health Immune health

Non GMO

Vegan

Certified Organic by Organic Certifiers

All ingredients are vegan and Non-GMO

All ingredients are vegan and Non-GMO

Formula

100 million CFU

6-12 months

5 strains

Seals/Symbols

USDA Organic

FDA Statement of Identity

Dietary Supplement

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

See for yourself

Organic Infant Liquid Probiotic 100 Million CFU Unflavored by Mary Ruth’s label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Organic Infant Liquid Probiotic 100 Million CFU Unflavored by Mary Ruth’s

These are the 5 active ingredients this product is made of. Select any to open its full monograph.

Serving size0.25 mL Dosage formLiquid Servings per container120 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Proprietary Probiotic Blend

2.5 mg per serving

Other (inactive) ingredients: Medium Chain Triglyceride Oil, Alfalfa Grass. These complete the product’s ingredient list but are not active constituents.

Interaction report

Organic Infant Liquid Probiotic 100 Million CFU Unflavored by Mary Ruth’s Drug Interactions

Want to check YOUR meds against Organic Infant Liquid Probiotic 100 Million CFU Unflavored?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
182Drugs
182 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Organic Infant Liquid Probiotic 100 Million CFU Unflavored with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Bifidobacterium longum infantis1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium longum with antibiotic drugs might decrease the effectiveness of B. longum.
Since B. longum preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. longum preparations by at least 2 hours.

Likelihood Probable Evidence D

Bifidobacterium bifidum1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium. bifidum with antibiotic drugs might decrease the effectiveness of B. bifidum.
Since B. bifidum preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. bifidum preparations by at least 2 hours.

Likelihood Probable Evidence D

Bacillus coagulans Unique IS-21 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking antibiotics with Bacillus coagulans might decrease the effectiveness of B. coagulans.
B. coagulans preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. coagulans preparations by at least two hours.

Likelihood Probable Evidence D
The maker

Brand information

Manufacturer and brand details for Organic Infant Liquid Probiotic 100 Million CFU Unflavored, from the product label.

Mary Ruth’s

See all Mary Ruth’s products
Name
MRO MaryRuth, LLC
City
Los Angeles
State
CA
ZipCode
90035
Phone Number
(310) 955-1353
Web Address
www.maryruthorganics.com
Pharmacist Counseling Corner

Organic Infant Liquid Probiotic 100 Million CFU Unflavored by Mary Ruth’s: Common Questions

Does Organic Infant Liquid Probiotic 100 Million CFU Unflavored by Mary Ruth’s interact with any medications?
Yes. Based on its ingredients, Organic Infant Liquid Probiotic 100 Million CFU Unflavored has a known interaction with 182 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Organic Infant Liquid Probiotic 100 Million CFU Unflavored contains 5 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I give this to my infant while they're on antibiotics?
Not at the same time. Antibiotics kill the live bacteria in probiotics, making them less effective. Space out the doses and mention both to your pediatrician so they can advise you on timing.
Is this safe for a newborn or preterm infant?
Preterm and critically ill infants need extra caution. Rare cases of infection have been reported in this group. Talk with your pediatrician before giving this to a premature or seriously ill baby.
What are these bacteria supposed to do?
They're meant to support digestive health. Some evidence suggests Bifidobacterium bifidum may help with irritable bowel syndrome and respiratory infections, and Bacillus coagulans may help with constipation and irritable bowel syndrome, but overall evidence in infants is limited.
Are there any side effects?
Most infants tolerate it well. Rarely, babies have had abdominal discomfort, bloating, flatulence, or constipation. Very rarely, a dry cough was reported. If you notice any of these, mention it to your pediatrician.
Is it safe while breastfeeding?
Bifidobacterium bifidum is marked possibly safe during lactation, but data are limited. Talk with your doctor or pharmacist before using.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Organic Infant Liquid Probiotic 100 Million CFU Unflavored is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Organic Infant Liquid Probiotic 100 Million CFU Unflavored label
Sources

Sources & How We Checked

Organic Infant Liquid Probiotic 100 Million CFU Unflavored's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 48 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Bifidobacterium Longum 21 references
  1. Ha GY, Yang CH, Kim H, Chong Y. Case of sepsis caused by Bifidobacterium longum. J Clin Microbiol 1999;37:1227-8.
  2. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  3. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  4. Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. J Allergy Clin Immunol. 2012;130(6):1355-60. PubMed
  5. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  6. Pellonperä O, Vahlberg T, Mokkala K, et al. Weight gain and body composition during pregnancy: a randomised pilot trial with probiotics and/or fish oil. Br J Nutr. 2020 Nov 4:1-11. PubMed
  7. Pellonperä O, Mokkala K, Houttu N, et al. Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an at-risk group of overweight and obese women: A randomized, placebo-controlled, double-blind clinical trial PubMed
  8. Shahriari A, Karimi E, Shahriari M, Aslani N, Khooshideh M, Arab A. The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial PubMed
  9. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  10. Enomoto T, Sowa M, Nishimori K, et al. Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. Allergol Int 2014;63(4):575-85. PubMed
  11. US Food and Drug Administration (FDA). Dear Healthcare Provider Letter: Warning Regarding Use of Probiotics in Preterm Infants. September 2023. Available at: https://www.fda.gov/media/172606/download?attachment. Accessed November 1, 2023.
  12. Pillai A, Tan J, Paquette V, Panczuk J. Does probiotic bacteremia in premature infants impact clinically relevant outcomes? A case report and updated review of literature. Clin Nutr ESPEN. 2020;39:255-259. PubMed
  13. Sabaté JM, Iglicki F. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol 2022;28(7):732-744.
  14. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;52(11) PubMed
  15. Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 2015;107(1):56-9.
  16. Tamaki H, Nakase H, Inoue S, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc 2016;28(1):67-74.
  17. Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 2015;60(6):924-7. PubMed
  18. Esaiassen E, Cavanagh P, Hjerde E, Simonsen GS, Støen R, Klingenberg C. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis 2016;22(9):1664-6.
  19. Tena D, Losa C, Medina MJ, Sáez-Nieto JA. Peritonitis caused by Bifidobacterium longum: case report and literature review. Anaerobe 2014;27:27-30. PubMed
  20. Sangkanjanavanich S, Pradubpongsa P, Mitthamsiri W, Sangasapaviliya A, Boonpiyathad T. Bifidobacterium infantis 35624 efficacy in patients with uncontrolled asthma: A randomized placebo-controlled trial. Ann Allergy Asthma Immunol 2022;129(6):790-792. PubMed
  21. Wilson HL, Ong CW. Bifidobacterium longum vertebrodiscitis in a patient with cirrhosis and prostate cancer. Anaerobe 2017;47:47-50. PubMed

See these in context on the Bifidobacterium Longum monograph →

Bifidobacterium Bifidum 7 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682-7. PubMed
  4. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  5. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  6. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  7. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed

See these in context on the Bifidobacterium Bifidum monograph →

Bacillus Coagulans 20 references
  1. Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland 1989-1992. Clin Infect Dis 1996;22:564-6. PubMed
  2. Tynkkynen S, Singh KV, Varmanen P. Vancomycin resistance factor of Lactobacillus rhamnosus GG in relation to enterococcal vancomycin resistance (van) genes. Int J Food Microbiol 1998;41:195-204. PubMed
  3. Klein G, Zill E, Schindler R, et al. Peritonitis associated with vancomycin-resistant Lactobacillus rhamnosus in a continuous ambulatory peritoneal dialysis patient; organism identification, antibiotic therapy, and case report. J Clin Microbiol 1998;36:
  4. Kalima P, Masterton RG, Roddie PH, et al. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996;32:165-7. PubMed
  5. Goldin BR. Health Benefits of probiotics. Br J Nutr 1998;80:S203-7. DOI
  6. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60.
  7. MacGregor G, Smith AJ, Thakker B, Kinsella J. Yoghurt biotherapy: contraindicated in immunosuppressed patients? Postgrad Med J 2002;78:366-7. PubMed
  8. Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-81.
  9. De Groote MA, Frank DN, Dowell E, et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005;24:278-80. PubMed
  10. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47(5):437-9. PubMed
  11. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  12. Sendil S, Shrimanker I, Mansoora Q, Goldman J, Nookala VK. Lactobacillus rhamnosus bacteremia in an immunocompromised renal transplant patient. Cureus. 2020;12(2):e6887. PubMed
  13. Albarillo FS, Shah U, Joyce C, Slade D. Lactobacillus rhamnosus Infection: A single-center 4-year descriptive analysis. J Glob Infect Dis. 2020;12(3):119-123. PubMed
  14. Pasala S, Singer L, Arshad T, Roach K. Lactobacillus endocarditis in a healthy patient with probiotic use. IDCases. 2020;22:e00915. PubMed
  15. Agrawal S, Tuchman ES, Bruce MJ, Theodorou ME. Fatal Lactobacillus endocarditis in a patient with transcatheter aortic valve replacement. BMJ Case Rep. 2020;13(11):e236835.
  16. Antoun M, Hattab Y, Akhrass FA, Hamilton LD. Uncommon pathogen, Lactobacillus, causing infective endocarditis: Case report and review. Case Rep Infect Dis. 2020;2020:8833948. PubMed
  17. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  18. Franko B, Vaillant M, Recule C, Vautrin E, et al. Lactobacillus paracasei endocarditis in a consumer of probiotics. Med Mal Infect. 2013;43(4):171-3. PubMed
  19. Campbell RE, Miller A, Afroze A. Native valve endocarditis secondary to Lactobacillus paracasei bacteremia. Consultant. 2020;60(9):27-8. DOI
  20. Kato K, Funabashi N, Takaoka H, et al. Lactobacillus paracasei endocarditis in a consumer of probiotics with advanced and severe bicuspid aortic valve stenosis complicated with diffuse left ventricular mid-layer fibrosis. Int J Cardiol. 2016;224:157-161. PubMed

See these in context on the Bacillus Coagulans monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring